Capital Building in Washington DC

Advocacy & Policy

To improve patient care, ASCO advocates for increased federal funding for research, greater health care access, value in cancer care, and payment reform.

  • 2020 Fee Schedule Proposal Outlines E&M Code Changes, MIPS Changes

    CMS is proposing to align Evaluation & Management (E&M) coding with changes laid out by the Current Procedural Terminology Editorial Panel for office/outpatient E&M visits, along with proposed changes to the Quality Payment Program.

    Read More
  • Drug Pricing Bill Should Protect Patients, Encourage Interoperability

    ASCO submitted comments to a Senate Finance Committee markup on the “The Prescription Drug Pricing Reduction Act (PDPRA),” a package of proposals aimed at addressing the high cost of prescription drugs.

    Learn More
  • Proposed Opioid Blister Packaging Requirements and Cancer-Related Pain

    In a comment letter to the acting FDA commissioner, ASCO expressed concerns that a proposed modification to the existing Opioid Analgesic Risk Evaluation and Mitigation Strategy (OA REMS) could adversely affect patients with cancer-related pain.

    Read More

Random Quote

"As medical professionals and as a Society, we must all continue to evolve and transform cancer care and research with each new discovery."
Julie M. Vose, MD, MBA, FASCO
ASCO President, 2015-16